778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma - Gino K In; James Larkin; Yazan Samhouri; Marcus Butler; Victoria Atkinson; Jeffrey Chou; Juan Martin-Liberal; Patrick Terheyden; Sajeve Thomas; Wen Shi; Xiao Wu; Andrew S Poklepovic; et al. (Journal for ImmunoTherapy of Cancer, 2023)